Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) CFO Jason Haas acquired 1,000 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were bought at an average price of $20.00 per share, for a total transaction of $20,000.00. Following the acquisition, the chief financial officer owned 62,908 shares of the company’s stock, valued at approximately $1,258,160. This represents a 1.62% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Odyssey Therapeutics Trading Up 0.2%
ODTX opened at $17.94 on Thursday. Odyssey Therapeutics, Inc. has a 52-week low of $15.35 and a 52-week high of $20.30.
Further Reading
- Five stocks we like better than Odyssey Therapeutics
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
